13FPulse
CE

CELC CELCUITY INC

2026Q2 · CUSIP 15102K100 · Sector: Healthcare & Biotech

Exiting + falling

Funds leaving and price falling — historically weak for the next six months

Funds that own it
270
Institutions that reported holding it to the SEC
Net decrease in holders
4
Last quarter 274 → now 270
How unusual is that
Below average
Stronger than only 23% of US stocks
What the filings say, in one paragraph

270 funds held CELC at the end of 2026Q2, down 4 from the quarter before. Buying is stronger than only 22.7% of US stocks, and the price fell over the same quarter — funds leaving and price weakness at the same time. CELC has had 7 buying rushes in its history, and the price moved +6.2% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2017Q4: holders=38 2018Q1: holders=38 2018Q2: holders=47 2018Q3: holders=44 2018Q4: holders=43 2019Q1: holders=45 2019Q2: holders=47 2019Q3: holders=46 2019Q4: holders=47 2020Q1: holders=42 2020Q2: holders=36 2020Q3: holders=30 2020Q4: holders=29 2021Q1: holders=39 2021Q2: holders=66 2021Q3: holders=62 2021Q4: holders=53 2022Q1: holders=52 2022Q2: holders=41 2022Q3: holders=30 2022Q4: holders=39 2023Q1: holders=41 2023Q2: holders=56 2023Q3: holders=57 2023Q4: holders=58 2024Q1: holders=79 2024Q2: holders=93 2024Q3: holders=105 2024Q4: holders=103 2025Q1: holders=94 2025Q2: holders=97 2025Q3: holders=176 2025Q4: holders=238 2026Q1: holders=274 2026Q2: holders=270 -79 -39.5 +0 +39.5 +79 26157288 17Q418Q419Q420Q421Q422Q423Q424Q425Q426Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 7 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2026Q1 Top 10%
2025Q4 Top 10% +31.4%
2025Q3 Top 5% +15.8% +52.2%
2024Q2 Top 20% -14.7% -20.5%
2024Q1 Top 20% +3.4% -24.5%
2023Q2 Top 20% +26.2% +67.1%
2021Q2 Top 10% -7.6% -43.3%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
146
Change in large funds
+9
Total value they hold
$5.9B
Funds buying for the first time
60
Funds that sold out entirely
64
Price change that quarter
-27.2%
Funds holding puts (bearish)
5
Funds holding calls (bullish)
7

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)
EPS (TTM)
$-4.30
EPS YoY
Revenue (TTM)
Revenue YoY
Net margin
ROE
Debt ratio
101.5%
FCF (TTM)
-$192M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2021-09-30: EPS -0.41 2021-12-31: EPS -0.44 2022-03-31: EPS -0.53 2022-06-30: EPS -0.67 2022-09-30: EPS -0.75 2022-12-31: EPS -0.69 2023-03-31: EPS -0.55 2023-06-30: EPS -0.66 2023-09-30: EPS -0.83 2023-12-31: EPS -0.65 2024-03-31: EPS -0.64 2024-06-30: EPS -0.62 2024-09-30: EPS -0.70 2024-12-31: EPS -0.87 2025-03-31: EPS -0.86 2025-06-30: EPS -1.04 2025-09-30: EPS -0.92 2025-12-31: EPS -0.97 2026-03-31: EPS -0.97 2026-06-30: EPS -1.44 -1.58 -0.79 0.00 20212022202320242025202606/26 EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

Quarterly free cash flow
-55M-28M0K 20162017201820192020202120222023202420252026
Latest quarter $-55M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.